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as&in For 210 days and no heprln ,n = 12): b) 110 aspirin for 
~10 days bu1 hawin, I0.000 ill. at the lime of c&htterizalion 
(n = 5i: 0 WI& 300 m&lay. for PI least 5 days In = Il. 
Patients undergoing cwwwy angic@sty were randomly as. 
signed to shwt-term treatment wtth aspirin given as a) 75 mglday 
and I97 t 93. In pa& at~&tring sspirta, I&W mg, daring 
angiopldrty. tl-dchydm-thmmboxanc B, averaged 151 * 66, 
t38 = 53 and 133 + 77, mpetively. 
Conclusions. Enhawed thmmbuunc bimynthesis aswciated 
wilh cardiac cslheterizatim “I ~lrwwy pn y can be 
largely suppressed by law dose aspirin. Tbii tiwXtg is m&tent 
with the view that tbts attemtton re&cts plst&t activation. 
(J *in co,, cordial 1993:2*:131377-81, 
Episodic incwases in thromboxane AI biosynthesis have 
been detected in patients with unstable angina I l-3). Thew 
can he largely suppressed by low dose aspirin but not by 
coronary vasodilatorr (3). However, despite >95% suppres- 
sion of platelet cyclooxygenase activity. as monitored ex 
v/w. incomplete suppression of in viva thromboxane A2 
biosynt;&s NIS occasionally seen during Icw doss aspirin 
therapy. Episodic platelet activation. as seen in unsmble 
angina. i, likely to reflect a dynamic thrombotic process 
often assocmted with fissuring ofan atherosclemtiL plaque in 
a major coronary artery (4.5). 
Percutaneous tnnsluminal coronary angioplasty induces 
a “controtled injury” afthe intima. media and adventitia OF 
the diseased nnerial segment, with rapid deposition of plate- 
lets at the sate of dilation (6). This procedure is consistently 
a:rociated wirh transient increases in thromboxane A, bio- 
synthesis by up to I5 limes the basal rate (3.7). Given [he 
predictable nature of such acute biochemical changes. it 
seemed of interest to use this clinical model of intncoronary 
platelet activation to reassess the doi’ Qeoendence for the in 
r 
viva suppression of lbromboxane A, biosynthesis by aspirin. 
Because catheter-induced vascular trauma might also induce 
platelet activation (8) and because hepario is routinely ad- 
ministered to patients undergoing coronary angioplasty. we 
also studied the effects of aspirin and heparin on thrombox- 
ane A, biosynthesis in patients undergoing cardiac catheter- 
ization. 
Methods 
Patients. The study’s only inclusion criteria were I) the 
performance of either elective left heart catheterization by 
the standard Judkins technique or elective single-vessel 
coronary angioplasty. and 2) aspirin intake on various regi- 
mens (see later) during the 3 to IO days before the procedure. 
Informed consent was obtained from each subject. The 
study promcol was approved by the institutional Research 
Ethics Committee on October II, 1989. 
Between November 1989 and December 1990.57 patients 
from the same medical center were entered into the study. 
The mean age z SD was 57.9 -’ i0.4 years; 42 patients were 
male and 15 were female. Elective lefl heart catheterization 
was performed in 28 patients and single-vessel coronary 
aagioplasty in 29. The baseline clinical characteristics of the 
patients undergoing catheterization and of those undergoing 
coronary angioplasty are shown in Table I. None 01 thi 
clinical features difiered significantly between the two 
groups. 
Patien!s undergoing elective coronary angioplasty had 
~75% stenosis ofthe left anterior descending, left circumflex 
or right coronary artery. An average of 3.6 + 0.4 (range I to 
8) consecutive connary dilations were. performed at the site 
of the stenosis. each lasting 112 2 44 s (range 30 to 240), at 
a pressure oi5.3 f 1.4 atm (range I.6 to 8). 
Treatment subgroups. Patients undergoing cardiac cath- 
eterization were randomly assigned to one of the following 
treatment groups: a) no aspirin for 210 days and no kzparin 
at the time of catheterization (n = 12); b) no aspirin fo; 210 
davs but hetwin. iO,OKl Ill. administered as an intravenous 
b&s at thd time of catheterization (n = 5); or c) aspirin, 
3W o&day for ~5 days (n = II). 
Ail patients undergoing coronary angiopiasty reccivzd an 
intravenous balus of heparin, 10,000 IU. immediately befor: 
the pro&x. ThZj e!so :eceived aspiria according !c oz 
ofthe following regimens: a) 75 mg/day for sS days (n = I I): 
2 of these 11 patients received IS0 mglday and were ex- 
eluded from the analysis; b) 300 mglday for t3 days (n = 9); 
or c) 300 mg/day for 23 days followed by i,OilO mg as a 
continuous intravenous infusion over the 2 h of the pr~e- 
dure (n = 9). Treatment was allocated according to a 
predefmed randomization sequence that was unknown to the 
investigators. Ethical considerations dictated the di&rent 
design of the catheterization and coronary angioplasty stud- 
ies. The choice of aspirin regimens was aimed at exploring 
the wge ofdaily doses used in clinical vials of patients with 
unstable coronary syndromes. 
Other drugs, such as beta-adrenergic btockiog agent<, 
calcium channel blocking ageots, nitrate derivatives and 
diuretics, were equally distributed among the patient sub- 
groups. There were no significant differences among sub- 
groups with respect to gender, body mass index, previous 
myocardial infarctions and risk factors, except for a more 
frequent (p < 0.05) family history of coronary artery disease 
in patients receiving 3uO mglday of aspirin compared with 
those receiving IS mglday. In addition, patients receiving 
75 &day of aspirin were older than those oo the 300 + 
I.O@l mg regimen (65.4 + 8.1 vs. 52.0 ? 6.8 years, p = 0.03). 
Urine cdIecticms aad smcedwe d&its. Three coose~“- 
live urine collections w&e obtained from all patients for the 
analysis of I I-dehydro-thromboxan B,. a major enzymatic 
derivative of thromboxane A, (9.10), one before catheteriza- 
tion or coronary angioplasty (over 3.0 * 2.4 h), another 
encompassing the whole procedure (over 5.5 + 2.3 h) aad 
the third after the procedure (over 3.8 * 2.7 h). The timing 
and total volume of each urine sample was recorded. and a 
50 ml aliquor was frozen and stored at -2Or until analysis. 
Asrsy of urinary Il.dehydro.lhromboxam 8,. Imm&- 
reactive II-dehvdro.thromboxane B, wasextracted fmm IO 
ml aliquots of each urine sample (th;pH was adjusted to 4.0 
lo 4.5 with fomdc acid) on SEP-PAK Cl8 cartridges (Waters 
Associates) and eluted with ethyl acetate as previously 
described (IO.1 I). The eluate was subjected to silicic acid 
column chromatography and further eluted wth benzene: 
ethyl acetate:methanoi (6 :40:30). The overall recovery, as 
determined by the addition of I I-debydrcr-(‘HI thromboxane 
B,. averaaed SO ? 6%. lmmunoreactive I I-dchvdro- 
thromboxane B, &ted from silicic xid columns was as- 
sayed al final dilution ranging fmm ::I5 to i:i,ooO. The 
Figure I. ur;.rq cI:EkJii 3,: cf !! dcb;d:c :b?dxxz~: 3, 
(TXBJ in patwets before. during and after cardiac catheteriz-.tmn. 
A statistically sig~inificani i crease IS prrsm in palienls who did not 
receive any Lieatmenr befoie cathe~eriradon a$ wrii as tn rhore 
receiving hepari‘n intnvenourly Cv.). Ir: the paticnta who recewed 
aspirin (ASA) hefore cathelerizalion, the baaal rate of I I.drhydrw 
thromboxane B2 excretion is significantly lower than that m Ihc 
other two lrealmtn, groups and the procedure-relaed mcrcdx I” 
thramborane A, biosynthesis i  fatally abolished. ‘p < 0.01 versus 
the valuebeforecatheterim[ion. tp < 0.01 vwws the noaspinn. no 
hepain 8m”p and the hcparin ~ruup. 
assays were performed without knowledge of the clinical 
data and allocated treatment. 
Statistical snalysis. For the clinical data. continuous vari- 
ables were compared by one-wy aimlysi; of rnti:-ace. wd 
frequencies of observations by the Fisher twotailed exact 
probability test. Having established that metabolite excre- 
tion rates x:e not normally distributed in all treatment 
groups, we used a nonparametric approach tu statistical 
analysis of the biochemical measurements. Data were sub 
jetted to analysis of variance by the Friedman test. followd 
by the Mann-Whitney test as appropriate (12). Statistical 
significance was defined as p c 0.05. Al: values are ex- 
pressed as mean value + SD. 
Results 
Compliitions. One patient in the hi$ha dose aspirin 
group undergoing coronary angioplasty developed total oc- 
clusion at the angioplasty sire immediately after the proce- 
dure 8. ’ was treated with intmcomnary streptokinase. 
There were no bleeding complications that required blood 
transfusion. 
ILdehydro-lhromboxr B, excretion in patients undergo- 
iap wdii wtbetaization. A total of 175 urine samples were 
analyzed for 1 I-dehydro-thmmhoxane BI in the six groups of 
subjects (n = 57) studied. In four patients undergoing coronwy 
rmgioplaaty an additional urine collection was performed be- 
fore the procedure. The meawrements obtained in pattents 
undergoing cardiac catheterization are depicted in Figure I. In 
the patients who had not received aspirin for al0 days and 
were not given hepain at the lime of caixterization. this 
procedure was ax&ted with a statistically signiticant (p < 
0.01) tbreefold increase in metabulite excretion. This increase 
is quite comparable to the changes in either IldehyJm 
thromtwane B? (3) or 2.3dinor.thromboxaw B, (7) observed 
dotine angioplasty in patients not treated with aspirin. How- 
ever. I IdehydrMbromboxane BZ remained Ggnificandy in- 
creased after cardiac catbetedration. ai variance v.-:ih the 
substantial decrease xp&d after angioplasty (3.7). A vinu- 
ally identical pattern of metabolite excretion was wied h 
patients who did receive heparin at the time of catheterization 
(Fig. I). In contest. in the patients who received aspirin, 
300 mdday, for at least 5 days before catbeterizalion. the basal 
mte of I I-dehydro-thmmboxane B, excretion was significantly 
tp < 0.01) lower than thal in lix u&two trexL%ent groups 
and the procrdure-related increase in thmmboxane A, hiosyn- 
thesis was tomtly abolished. In compuisnn with findings in the 
other two weument gmoups. IldehydrMbmmbaxaoe 8, ex- 
cr.&n during catheterization was wppressed by appmxi- 
maely 87%. 
Camplri.wn of aspirin ngbwns in patients 
giaplauy. The measurements obtained in patients wdergo~ 
coronary angioplrsty during trea~m-ent with different aspirin 
regimens are depicted in Figure 2. No statistically signiticant 
differences in basal metabolite xcreti~ were found among!h 
three treatment groups. The previwsly reported (3.7) increae 
in thmmboxane Al biosynthesis associated with cornnary 
angioplarty was similarly at&bed by the three regi~netts of
aspirin therapy. This finding is consistent with the earlier 
finding 113) the! 75 mglday is already at the top of the dose- 
respocse curve for inhibition of platelet cyclooxygenase acdv- 
iry on repeated aily dosing in healrhy subjects. Although the 
data lor the 75 &day and 300 mg/day gmmups are quite 
comparable. the values of I I-dehydrc-rhromboxxane B2 exre- 
tion tended to be somewhat Iowcr in the patients who also 
received aspirin as a continuous intwenous infusion over the 
2 h of the procedure (Fig. 2). 
Discussion 
Our study demonstrates that the vascular trauma prc- 
duced by left heart catheterization and angiography by the 
Judkins technique causes a transient increase of thrombox- 
ane A, biosynthesis comparable to that previously reported 
after coronary angioplasty (3.7). This increase is unaffected 
by pretreatment with heparin but is suppressed by X35% 
after pretreatment with aspirin, 3M) mglday. The sludy also 
indicates thal thromboxaee AZ biosynthesis after coronary 
aztgioplasty is only slightly reduced by increasing the dose of 
aspirin to >75 mg/da) 
F&d6 cd cardiac a+Plhelerization on plalelot activation. 
The standard vascular trauma of arterial and venipuncture 
and of catheter manipulation associated with standard left 
heart catheterizatton and venous insertion of an infusion line 
are associated with an increase of thrombonane A, hiosyn- 
thesis similar to that observed during coronary angtoplasty 
(3,7). This unexpected obseration :ugggests that the addi- 
tional vascular trauma related to coronary plaque disruption 
does not cause an additional detectable increase of platelet 
activation. There are several possible explanations for this 
finding. The magnitude of the vascular trauma of arterial and 
venous puncture, and the successive local compression to 
stop bleeding, might so increase lhromboxane A, biosynthe- 
sis that a further increase related to the localized disruption 
ofthe plaque would not be oetectable because of the already 
elevated background related to the catheterization. More- 
over, it should be considered that an integrated measure of 
urinary I I-dehydro-thromboxane B, (3) or 2,3-dinor- 
thromboxane B, (7) ever a few hours does not allow en 
accurate assessment of the timing and duration of stimuli 
operating in viva to cause platelet activation. Thus. one 
muld speculate that coronary an8io~last~ might tritxer a 
stronger negative feedback m&hat% (enhanc>d pro&y- 
clin release, for example [71! resulting in a less prolonged, 
although presumably more intense. stimulus to thromboxane 
A, biosynthesis. The different time course of metabolitc 
excretion after the two procedures (Fig. I) (3.7) is consistent 
with this suggestion. Heparin had no measurable int?i;xxe 
on the increase in urittay II-dehydro-thromhoxane B, ex- 
cretion during catheterization. thus suggesting that heparin- 
suppressible coagulation events are not involved in this 
phenomenon. 
Dose-dependent effect of aspirin during angioplasly. The 
increase of aspirin dose to ~-75 mg/day was associated with 
a trend toward decreased thromboxane A, biosynthesis and 
with a reduced intersubject variability.-This. very slight 
dose-dependent effect is compatible with the biochemical 
pharmacology of pla:elet cyclooxygenase inhibition by aspi- 
rin on repealed daily dosing (13). The addition of a larger 
dose of aspirin. administered by continuous intravenous 
infusion during coronary angioplasty resulted in numerically 
lower excretion rates of the thromboxane metahabdite. This 
finding suggested that :hc residual !5% thromhoxane AZ 
biosynthesis during treatment with 75 to 300 mgJday of 
aspirin reflects the contribution of extraplatelet sources of 
thromboxane A2 that may be more resistant to the effects of 
aspirin. However, no measurements of other urinary ei- 
casanoids from extraplatelet sources hat been peifomxd 
to substantiate this suggestion. 
Assuming a mean value of metabolite excretion during 
coronar,! :ngioplesty ,.c ----n-;--*-l*, I .6X! pg/mg cread- “. “rr.“” . . . . “..,, 
nine in the absence of aspirin (that is, assuming a degree of 
plateiet activation at least comparable to that observed 
during catheterization in the patient groups not treated with 
aspirin), the levels of urinary I I-dehydro-tbromboxane 8, 
actually measured during coronary angioplasty would repre- 
sent approximwely 86% suppression (with 75 mglday) to 
91% suppression <with l,X!O mg) of the acutely enhanced 
thromboxane AZ biosynthesis associated with this proce- 
dure. The lack of statistica! siprificance of this 5% difference 
may he related to the small sample size of the different 
treatment groups. 
A further decline in II-dehydro-thromboxane Bz excre- 
tion with 1,308 mg versw 325 mglday was also noted by 
Force et al. (14) in patten:s with stable coronary artery 
disease during combined administration of aspirin and 
omega-3 fatty acids. However, the reduction in metabolite 
excretion associated with 325 mg was not significantly dif- 
ferent from that achieved during administration of SO and 
100 mg/day (14). 
Conclusions. Enhanced thromboxane biosynthesis asso- 
ciated with cardiac catheterization or coronary angioplasty 
can be largely suppressed by low dose aspirin thempy, 
consistent with these biochemical changes reflecting platelet 
activation. Extreplatelet sites of thrombaane biosynthesis 
do not appear to be affected by low dose aspirin and might 
respond to incicased or more frequent dosing, or both. The 
results of this study are co&rem with the apparent lack of 
a dose dependence for the antithromtmtic effect of aspirin. 
75 to 1.3CnJ muday. as demonstrated in studies of unstable 
angina (IS-17). Whether a low dose aspirin regimen can 
provide a safe and effective alternative to e higher dose 
combined with dipyridamoie for the prevention of paipro- 
cedural thwmbatic complications of coronary angioplasty 
(18) remains to be established. 
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